GlassScriptPhysician profile
Josh A Showalter
NPI 1407299076
$493.69
in general payments reported to CMS, 2019-2025
14 companies · $135 in 2025
The $135 reported for 2025 was more than what a typical Anatomic Pathology & Clinical Pathology provider received nationally (typical 2025 total: $50.59).
See the full distribution for Anatomic Pathology & Clinical Pathology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $238 · 2022: $57.89 · 2023: $16.65 · 2024: $46.79 · 2025: $135.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $197.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $86.13 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $67.57 | 2019-2025 | Fruzaqla |
| Merck Sharp & Dohme LLC | $59.02 | 2024-2025 | Keytruda, Keytruda Qlex, Welireg |
| Celgene Corporation | $56.51 | 2019-2023 | Reblozyl |
| Amgen INC. | $43.10 | 2019-2022 | |
| Ipsen Biopharmaceuticals, INC | $40.75 | 2025 | Somatuline Depot, Onivyde |
| Jazz Pharmaceuticals INC. | $30.91 | 2025 | |
| Eisai INC. | $21.20 | 2022 | |
| Genzyme Corporation | $18.91 | 2022 | |
| Rigel Pharmaceuticals, INC. | $16.05 | 2019 | |
| Agios Pharmaceuticals, INC. | $14.27 | 2019 | |
| Seagen INC. | $14.14 | 2019 | |
| Amag Pharmaceuticals, INC. | $13.65 | 2019 | |
| Incyte Corporation | $11.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Josh Showalter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.